首页>投融资
Emglev Therapeutics
收并购
Emglev Therapeutics 是一家生物技术公司,成立于 2023 年,是居里研究所的衍生公司,致力于发现和开发变革性的免疫疗法,以解决肿瘤学领域未满足的医疗需求。通过利用其独特的专有平台,公司打破了当前传统抗体发现的障碍,以提供独特的靶点和 sdAb,这些靶点和单抗体完全在体外选择,并针对任何靶点以任何形式进行治疗应用验证。该公司专注于开发更高水平的免疫疗法,以造福所有具有高度未满足需求的患者。
基本信息
-
公司全称Emglev Therapeutics
-
类型免疫疗法研究商
-
产业领域药品研发/制造、生物药
-
公司人数不明确
-
地址Incubateur Paris Santé Cochin 24 Rue Du Faubourg Saint Jacques 75014, Paris
-
联系电话
-
邮箱contact@emglev-therapeutics.com
-
成立时间2023-01-01
投融资
-
2024-09-30收并购未透露未透露
相关投融资企业
捐赠/众筹/授予
igaTx 是一家生物技术公司,开发工程化单体 IgA 中性粒细胞接合器,以释放中性粒细胞对癌症的肿瘤杀伤能力,以及针对传染病的工程化二聚体 IgA 杀伤能力。该公司在工程治疗性 IgA 方面的前沿方法基于 Jeanette Leusen 教授在乌得勒支医学中心(荷兰乌得勒支)进行的开创性工作,并广泛适用于许多不同疾病。
C轮
SiteOne Therapeutics, founded by Stanford University, is a biotechnology company focused on the development of long-acting analgesics, non-norcotic analgecis and diagnostic imaging agents for pain and cancer.In May 2023, SiteOne Therapeutics Inc received a grant for up to $15 million from the National Institute on Drug Abuse.In January 2017, the company raised $15 million in a series B round of financing
A轮
PsiOxus Therapeutics Ltd was formed from the merger of Myotec Therapeutics and Hybrid BioSystems in December 2010. The company is focused on the development of novel therapeutics that address cancer and other clinically unmet diseases.Myotec Therapeutics was a spin-out from Imperial Innovations and was set up to develop technology originated at Imperial College London. It focused on repurposing drugs for the treatment of cachexia, with the intention of out-licensing after completion of phase II studies.In June 2017, the company expanded its operations into a 21,000 sq ft state-of-the-art facility on the Abingdon Science Park in Oxfordshire, UK and a new US facility in Plymouth Meeting near Philadelphia, PA.In April 2012, PsiOxus announced that it would expand into new facilities at the Milton Park in Oxfordshire, UK. The expansion would include a bespoke laboratory for the research and development of novel viral therapeutics; later that month, the facility was opened.By Decem